News

• BlueLinx Announces CEO Succession
  04/21/2021 / 22:30 - GlobeNewswire
•  
• Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
  04/21/2021 / 13:30 - GlobeNewswire
•  
• BlueLinx to Host First Quarter 2021 Results Conference Call and Webcast
  04/20/2021 / 22:30 - GlobeNewswire
•  
• Cyclerion Therapeutics to Host Pipeline Update Webinar
  04/20/2021 / 13:00 - GlobeNewswire
•  
• Advantage Solutions Announces First Quarter 2021 Earnings Release Date and Conference Call
  04/19/2021 / 14:00 - GlobeNewswire
•  
• Clark Capital Welcomes Jim Warren as Chief Operating Officer
  04/06/2021 / 14:00 - GlobeNewswire
•  
• Makara Opens Waitlist for First Ever SEC Registered Crypto Robo-Advisor
  03/30/2021 / 15:00 - GlobeNewswire
•  
• Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide
  03/30/2021 / 13:57 - GlobeNewswire
•  
• Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
  03/30/2021 / 07:21 - GlobeNewswire
•  
• Trinity Alps Private Investment Business Marks 1st Anniversary with $450M+ AUM
  03/24/2021 / 20:04 - GlobeNewswire
•  
• Cyclerion Therapeutics Announces Departure of Chief Medical Officer
  03/18/2021 / 22:00 - GlobeNewswire
•  
• Advantage Solutions to Participate at Jefferies Virtual Business Services Summit
  03/18/2021 / 21:05 - GlobeNewswire
•  
• Advantage Solutions Reports Fourth Quarter and Full Fiscal Year 2020 Financial Results Above Prior Outlook and Raises 2021 Adjusted EBITDA Expectation
  03/16/2021 / 21:05 - GlobeNewswire
•  
• Fulcrum Partners Reports on Executive Benefits Post 2020
  03/16/2021 / 15:00 - GlobeNewswire
•  
• Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide
  03/16/2021 / 13:32 - GlobeNewswire